Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07761806
PHASE2/PHASE3

Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.Erectile dysfunction (ED) is one of the commonest disorders in adult males and affects 12-19% of men of reproductive age.Erectile dysfunction can be due to vasculogenic, neurogenic, hormonal, veno-occlusive, psychogenic and/or pharmacogenic factors. PRP is autologous plasma that has a platelet concentration above the concentrations typically found in whole blood and is derived from the patient's own blood (autologous) through a process of centrifugation. PDE5Is inhibit the enzyme phosphodiesterase-5 (PDE-5) leading to dilatation of the penile arteries leads to a more prolonged erection.

Official title: Comparison Between The Effect of Intracavernosal Injection of Platelet-Rich Plasma as a Single Agent vs Daily Oral 5 Phosphodiesterase Inhibitor Intake as a Single Agent Vs Combination In Improving of Erectile Dysfunction

Key Details

Gender

MALE

Age Range

30 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2024-01-15

Completion Date

2024-10-01

Last Updated

2026-08-12

Healthy Volunteers

No

Interventions

DRUG

Tadalafil 5mg

To compare between Intra Cavernous Injection of Platelet Rich Plasma (PRP) as a single agent , 5 PDE inhibitor as a single agent vs combined effect of two agent to achieve an efficient therapy with less cost for the treatment of Erectile Dysfunction.

Locations (1)

Ain Shams University Hospital

Cairo, Abbasia, Egypt